Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk in overweight patients:: 1-year experience from the RIO-Europe study (vol 365, pg 1389, 2005)

被引：0
|
作者：
Van Gaal, LF
Rissanen, AM
Scheen, AJ
Ziegler, O
Rössner, S
机构：
来源：
LANCET | 2005年 / 366卷 / 9483期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：370 / 370
页数：1
相关论文
共 8 条
  • [1] Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
    Van Gaal, LF
    Rissanen, AM
    Scheen, AJ
    Ziegler, O
    Rössner, S
    LANCET, 2005, 365 (9468): : 1389 - 1397
  • [2] Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
    Pi-Sunyer, F
    Aronne, LJ
    Heshmati, HM
    Devin, J
    Rosenstock, J
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (07): : 761 - 775
  • [3] Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial (vol 295, pg 761, 2006)
    Rosenstock, J
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (11): : 1252 - 1252
  • [4] In overweight patients cannabinoid receptor blocker rimonabant better than placebo reduced body weight and waist circumference. Results of RIO-Europe trial
    不详
    KARDIOLOGIYA, 2005, 45 (09) : 96 - 97
  • [5] Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Satiety Signaling in Overweight People With Schizophrenia (vol 33, pg 118, 2013)
    Warren, Kimberly R.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 36 (01) : 26 - 26
  • [6] Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese patients Pooled 1-year data from the Rimonabant in Obesity (RIO) program
    Van Gaal, Luc
    Pt-Sunyer, Xavier
    Despres, Jean-Pierre
    McCarthy, Christine
    Scheen, Andre
    DIABETES CARE, 2008, 31 : S229 - S240
  • [7] Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors:: two year results from the RIO-Europe Study
    Van Gaal, Luc F.
    Scheen, Andre J.
    Rissanen, Aila M.
    Roessner, Stephan
    Hanotin, Corinne
    Ziegler, Olivier
    EUROPEAN HEART JOURNAL, 2008, 29 (14) : 1761 - 1771
  • [8] Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block -: The Swiss Beta Blocker in Spinal Anesthesia (BBSA) study:: A double-blinded, placebo-controlled, multicenter trial with 1-year follow-up
    Zaugg, Michael
    Bestmann, Lukas
    Wacker, Johannes
    Lucchinetti, Eliana
    Boltres, Anita
    Schulz, Christian
    Hersberger, Martin
    Kaelin, Gabriela
    Furrer, Lukas
    Hofer, Christoph
    Blumenthal, Stephan
    Mueller, Annabelle
    Zollinger, Andreas
    Spahn, Donat R.
    Borgeat, Alain
    ANESTHESIOLOGY, 2007, 107 (01) : 33 - 44
1